Georgia Clinical Trials

A listing of Georgia Clinical Trials actively recruiting patient volunteers.

Known as "The Peach State," Georgia was immortalized in the hit Ray Charles rendition of "Georgia On My Mind." Its biggest cities include Atlanta, Savannah, and Augusta, although Athens and Macon are both famous for their own reasons. Georgia is the #1 producer of peanuts and pecans in the U.S., and peanut-loving President Jimmy Carter was born and raised in the state. Vidalia onions, widely believed to be the world's sweetest onions, can only be grown in Georgia soil. The Emory University Health System is one of the South's leading healthcare innovators; its flagship Midtown location is found in Atlanta.

Search by Name
Search
Filter by Condition
2113 trials found

A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke

NCT05643573

Researchers are looking for a better way to treat people with atrial fibrillation and prevent stroke or systemic embolism (blood clots travelling through the blood stream to plug another vessel). Atrial fibrillation is a condition of having irregular and often rapid heartbeat. It can lead to the formation of blood clots in the heart which can travel through the blood stream to plug another vessel, and like this lead to serious and life-threatening conditions, such as a stroke. A stroke occurs b ...

Conditions: Prevention of Stroke or Systemic Embolism, Atrial Fibrillation

Closed Loop Glucose Control in Patients With Type 1 and Type 2 Diabetes

NCT05644730

This is a proof of concept safety study of an artificial intelligence based closed loop glucose control system designed for use in the intensive care unit setting. The type 1 and type 2 diabetic subjects in this study will have their glucose controlled to a range of 100-140 mg/dL by a novel artificial intelligence based closed loop glucose control system for a period of 24 hours. The subjects will consume three standardized meals during the 24 hour study period.

Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Phase: Not Applicable

Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia

NCT05646719

The objectives of this study are: To evaluate the safety and efficacy of Nyxol alone and with adjunctive low dose pilocarpine to improve distance-corrected near visual acuity (DCNVA) in subjects with presbyopia.

Conditions: Presbyopia

WW Improving Nutrition Study: A Randomized Controlled Trial

NCT05648344

The main objective of this study is to determine whether a behavior change weight management and wellness program (WW) delivered via an app for 6-months will be effective in improving diet quality in U.S. adult participants, relative to a control group through a randomized controlled trial.

Conditions: Overweight and Obesity
Phase: Not Applicable

A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight

NCT05649137

This study will look at how much weight participants will lose and how much blood sugar control they achieve from the start to the end of the study. The weight loss in participants taking the investigational high dose of semaglutide will be compared to the weight loss in people taking "dummy" medicine and a lower dose of semaglutide. In addition to taking the medicine, participants will have talks with study staff about healthy food choices and how to be more physically active. Participants will ...

Conditions: Obesity, Diabetes Mellitus, Type 2

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older

NCT05650554

The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of up to 3 dose levels of Quadrivalent Influenza messenger ribonucleic acid (mRNA) Vaccine MRT5413 compared to an active control (QIVstandard-dose (SD), QIV high-dose (HD) [adults ≥ 65 years of age only], or quadrivalent recombinant influenza vaccine (RIV4)) in adults 18 years of age and older.

Conditions: Influenza Immunization
Phase: Phase 1/2

DECOY20 Study in Patients With Advanced Solid Tumors

NCT05651022

INDP-D101 is a Phase 1, open-label, multi-center, dose escalation and expansion study evaluating the safety, tolerability and clinical activity of Decoy20 in patients with advanced solid tumors.

Conditions: Solid Tumor, Adult

A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation

NCT05652205

Functional constipation (FC) is a common healthcare problem in children of all ages, potentially due to genetic predisposition, inadequate fiber and fluid intake, and immobility. Currently, there are no pharmacological therapies approved for the treatment of FC. This study will assess adverse events and change in disease activity with linaclotide therapy in participants with FC. Linaclotide is an approved drug being developed for the treatment of FC in pediatric patients who meet modified Rome ...

Conditions: Functional Constipation (FC), Chronic Idiopathic Constipation (CIC)

VTX958 Versus Placebo for the Treatment of Moderate to Severe Psoriasis

NCT05655299

This is a study to understand if taking VTX958 daily orally is safe and effective in participants diagnosed with moderate to severe psoriasis (PsO). Approximately 200 patients will take VTX958 Dose A, VTX958 Dose B, VTX958 Dose C, VTX958 Dose D, or placebo. The study consists of a 30-day Screening Period (to see if a participant qualifies for the study), a 16-week double-blind period (a participant receives active Dose A, Dose B, Dose C, Dose D, or placebo), and a 4-week Follow-Up Period. The m ...

Conditions: Psoriasis

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)

NCT05658510

In this study, an investigational medication named BXCL501 is being tested for the treatment of episodes of agitation associated with bipolar I and bipolar II disorder, schizophrenia, schizoaffective and schizophreniform disorder. This study compares the study drug to a placebo.

Conditions: Agitation,Psychomotor, Bipolar I Disorder, Bipolar II Disorder, Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders

Evaluation of Product Performance of a New Silicone Hydrogel Multifocal Contact Lens

NCT05660577

The objective of this study is to evaluate the product performance of a new silicone hydrogel daily disposable multifocal contact lens, the Bausch + Lomb (kalifilcon A) Daily Disposable Multifocal Contact Lens, when worn by current soft contact lens wearers on a daily disposable wear basis

Conditions: Daily Disposable Multifocal Contact Lens is Intended for Use for the Correction of Refractive Ametropia (Myopia and Hyperopia) and Presbyopia
Phase: Not Applicable

A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough

NCT05660850

This Phase IIa, multicenter, randomized, double-blind, placebo-controlled, crossover study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamic (PD) effects of GDC-6599 compared with placebo in patients with a history of chronic cough.

Conditions: Chronic Refractory Cough (CRC) With Non-atopic Asthma, CRC With Atopic Asthma, Unexplained Chronic Cough, CRC With Chronic Obstructive Pulmonary Disease, CRC With Chronic Obstructive Pulmonary Disease With Chronic Bronchitis
Phase: Phase 1/2